Assessment of therapeutic effects of Sofosbuvir plus Ribavirin in patients suffering from hepatitis C virus with genotype 3

Aim: this study was designed to assess response,safety and side effects of sofosbuvir and ribavirin in patients of hcv with genotype 3 infection. design: an open labeled study place and duration: mayo hospital lahore and liver clinic of bahbood hospital,lahore,department of medicine,kmsmc,sialkot from october 2015 to february 2017. method: patients suffering from hcv infection were selected and their hcv-rna was done by (roche amplifier switzerland). all patients were given sofosbuvir 400mg daily and ribavirin 800-1200 mg in divided doses orally according to body weight for twenty four weeks. followed up after 2 weeks and then at 04 interval. the patients undergoing study had baseline investigations of cbc,tsh,bsr,pcr quantitative for hcv rna as well as genotype. result: three hundred and twenty confirmed cases of chronic hcv (genotype 3) naïve patients were included.180 (56.25%)) male and 140(43.75%) female. mean age of the patients was 45.66+ 10 years. after 2 weeks of treatment among 276 patients (86.25%) positive response i.e.; undetectable hcv-rna a very rapid virological response (vrvr) and at 4 weeks of treatment,rapid viological response (rvr) was seen among 302 patients (94.37%). 100% patients achieved early viological response (evr) after 12 weeks,however 4 patients developed breakthrough i.e.; pcr was positive at the end of treatment. among 316 patients who have attained end of treatment response,40 patients (12.65%) developed relapse after 3 month of stopping therapy,hence (svr 12) was seen among 276 patients (87.34%). biochemical response in the form of alt/ast normalization was in all patients. conclusion: this study supports that sofosbuvir and ribavirine has great efficacy,well tolerated regimen with a fewer side effect and can achieve svr in patients suffering from chronic hcv.